

Product News

Survey shows that health benefits of L-carnitine are well known by consumers

Basel, Switzerland, 10 January 2013 – A representative survey conducted by the German consumer research organization GfK shows that L-carnitine as well as its health benefits are well known by consumers. The survey was commissioned by Lonza Ltd, Switzerland, who markets high quality L-carnitine products under the Carnipure™ brand.

The representative online survey was done in December 2012 among more than 1000 German consumers who reported to be at least occasional consumers of any kind of dietary supplements and/or functional foods. L-carnitine was known among 43% of the respondents. Of those, 39% could correctly relate L-carnitine supplementation to beneficial effects for weight management, 27% to exercise and 20% to energy. In the age group of 20-39 year olds, even 50% of respondents were aware of L-carnitine, and in general more women than men seem to know it. In the subgroup of people who currently take L-carnitine supplements, 59% take it for the purpose of weight management, 33% for exercise and 10% for cardiovascular health.

“As the use of health claims under Commission Regulation (EU) No 432/2012 has been limited for health ingredients, it is important to see that L-carnitine is a very well established ingredient and end-consumers are aware of a large variety of health benefits of L-carnitine”, comments Marco Goßen, Sales Director Nutrition for Germany, Austria and Benelux.

Lonza's Carnipure™ ingredients can be found in a large variety of end products throughout the world. It is not only used in dietary supplements, but also in beverages, bars and functional food products. Lonza will continue to promote the benefits of Carnipure™ L-carnitine via various channels.

About Lonza

Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Products and services span its customers' needs from research to final product manufacture. It is the global leader in the production and support of chemical and biological active pharmaceutical ingredients. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is also the world leader in microbial control providing innovative, chemistry-based and related solutions to destroy or to selectively inhibit the growth of harmful microorganisms. Its activities encompass the areas of water treatment, personal care, health and hygiene, industrial preservation, materials protection, and wood treatment. In addition, Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Furthermore, the company is a leading provider of value chemical and biotech ingredients to the nutrition and agro markets.

Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel
www.lonza.com

Product News

Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza is not subject to the SGX-ST's continuing listing requirements. Lonza is subject to the listing rules of the SIX Swiss Exchange, which do not have specific requirements equivalent to the listing rules of the SGX-ST in respect of interested person transactions, acquisition and realizations, and delisting. In 2011, the company had sales of CHF 2.692 billion. Further information can be found at www.lonza.com.

Further Information

Lonza Ltd
Director Marketing and Sales Nutrition
Reto Renggli
Tel +41 61 316 8244
Fax +41 61 316 9244
reto.renggli@lonza.com

Lonza Group Ltd
Media Relations
Melanie Disa
Tel +1 210 316 9413
Fax +1 201 696 3533
melanie.disa@lonza.com